Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins | 502 | 35700-23-3 |
| Dose | Unit | Route |
|---|---|---|
| 2.50 | mg | P |
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.47 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| S (Water solubility) | 75 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K21,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 36 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 9, 1979 | FDA | PHARMACIA AND UPJOHN |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vomiting | 206.76 | 87.98 | 141 | 1434 | 788152 | 89838720 |
| Nausea | 127.66 | 87.98 | 123 | 1452 | 1110193 | 89516679 |
| Chest discomfort | 126.81 | 87.98 | 57 | 1518 | 138308 | 90488564 |
| Diarrhoea | 98.01 | 87.98 | 99 | 1476 | 939091 | 89687781 |
| Abdominal pain upper | 89.49 | 87.98 | 61 | 1514 | 332613 | 90294259 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vomiting | 221.23 | 89.98 | 141 | 1350 | 910534 | 109677274 |
| Nausea | 143.49 | 89.98 | 123 | 1368 | 1235567 | 109352241 |
| Chest discomfort | 125.04 | 89.98 | 56 | 1435 | 173792 | 110414016 |
| Diarrhoea | 101.32 | 89.98 | 98 | 1393 | 1139407 | 109448401 |
| Abdominal pain upper | 98.47 | 89.98 | 60 | 1431 | 349051 | 110238757 |
None
| Source | Code | Description |
|---|---|---|
| ATC | G02AD04 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Prostaglandins |
| FDA CS | M0017805 | Prostaglandins |
| FDA EPC | N0000175454 | Prostaglandin Analog |
| CHEBI has role | CHEBI:36063 | oxytocic |
| CHEBI has role | CHEBI:50691 | abortifacient |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D000020 | Abortifacient Agents, Nonsteroidal |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Incomplete miscarriage | off-label use | 156072005 | |
| Induction of labor | off-label use | 236958009 | |
| Cervical ripening procedure | off-label use | 236959001 | |
| Hydatidiform mole, benign | off-label use | 417044008 | |
| Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Third trimester pregnancy | contraindication | 41587001 | |
| Low blood pressure | contraindication | 45007003 | |
| Severe pre-eclampsia | contraindication | 46764007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Acute nephropathy | contraindication | 58574008 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Stenosis of cervix | contraindication | 83536006 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Gynecological Surgery | contraindication | ||
| Inflammatory Disease of Female Pelvic Organs | contraindication |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.79 | acidic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | CHEMBL | CHEMBL |
| ID | Source |
|---|---|
| 4018095 | VUID |
| N0000146433 | NUI |
| D00682 | KEGG_DRUG |
| 58551-69-2 | SECONDARY_CAS_RN |
| 20259 | RXNORM |
| C0007047 | UMLSCUI |
| CHEBI:3403 | CHEBI |
| 87Q | PDB_CHEM_ID |
| CHEMBL1237122 | ChEMBL_ID |
| CHEMBL1237105 | ChEMBL_ID |
| D002260 | MESH_DESCRIPTOR_UI |
| 5281075 | PUBCHEM_CID |
| C062843 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4044 | INN_ID |
| 7B5032XT6O | UNII |
| DB00429 | DRUGBANK_ID |
| 319432 | MMSL |
| 4358 | MMSL |
| d00588 | MMSL |
| 109057004 | SNOMEDCT_US |
| 109058009 | SNOMEDCT_US |
| 373455002 | SNOMEDCT_US |
| 4018095 | VANDF |
| 4022193 | VANDF |
| 001310 | NDDF |
| 004942 | NDDF |
| 7B5032XT6O | INXIGHT DRUGS |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Hemabate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0856 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | NDA | 19 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9442 | SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| carboprost tromethamine | Human Prescription Drug Label | 1 | 0409-0064 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 16 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-477 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-435 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-179 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-698 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-917 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-919 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 46708-777 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 55150-459 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 55150-459 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 62332-777 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-900 | INJECTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 65145-132 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-579 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| carboprost tromethamine | Human Prescription Drug Label | 1 | 68083-584 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 16 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-825 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 12 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1680 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70512-859 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-112 | SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 17 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 71839-137 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 9 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81298-5010 | INJECTION | 250 ug | INTRAMUSCULAR | ANDA | 18 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81665-202 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83270-002 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 11 sections |